Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats.

Objectives: The radiopharmacokinetic parameters of the therapeutic radiopharmaceutical (188)Re-lanreotide were compared in rats implanted with hepatocarcinoma tumours (n= 18) and healthy rats (n= 18).

Methods: Rats were injected with approximately 1.8 MBq (188)Re-lanreotide (0.